• Skip to main content
  • Skip to footer

University of Tennessee Research Foundation

Technology Transfer & Licensing

  • About
    • Our Mission
    • Foundation History & Details
    • Student Opportunities
    • Frequently Asked Questions
    • UTRF Staff
    • Projects & Partners
  • Technologies
    • Available Technologies
    • Express Licensing
  • For Innovators
    • UT Research Foundation Accelerate Fund
    • Resources
    • IDEA Tutorial & Manuals
    • Technology Transfer Process
    • Business Incubator
    • UTRF Technology Maturation Grant Funding
  • Industry
    • Industry Partnerships
    • Agreement Examples
  • Media
    • News
    • Newsletters
    • Tech Talks
    • Annual Reports
  • Contact

UTRF in the News

UTRF Administrator / April 26, 2023

University of Tennessee Research Foundation Ranks in Top 100 Worldwide Universities Granted Utility Patents in 2022

For Immediate Release April 26, 2023 KNOXVILLE— The University of Tennessee Research Foundation (UTRF) has ranked No. 81 in the Top 100 Worldwide Universities Granted Utility Patents in 2022, a list published by the National Academy of Inventors (NAI). The University of Tennessee continues to make a profound and tangible impact across the state and around the (read more)

UTRF Administrator / September 22, 2022

UTSI, NearSpace Launch secure Space Force STTR Phase I grant

The project will study Black Box-MCAT, an integration of NSL’s Black Box EyeStar with UTRFs patent pending µSTAMPS Thruster technology The United States Space Force recently awarded a Small Business Technology Transfer (STTR) Phase I grant to the University of Tennessee Space Institute (UTSI) and NearSpace Launch (NSL) during its first-ever round of funding. This (read more)

UTRF Administrator / April 21, 2022

UTRF Licensee Veru, Inc. Announces Positive Results of COVID-19 Therapy’s Phase 3 Clinical Study, Seeking Emergency Use Authorization from FDA

UT Research Foundation licensee Veru, Inc. announced on April 11, 2022, that their Phase 3 clinical trial of sabizabulin as an oral therapy for hospitalized severe COVID-19 patients at high risk for Acute Respiratory Distress Syndrome (ARDS) and death showed the drug to be safe and effective. The trial was halted early due to the (read more)

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Interim pages omitted …
  • Page 22
  • Go to Next Page »

Footer

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Multi Campus Office

400 W. Summit Hill Drive
UT Tower 961A
Knoxville, TN 37902
Phone: 865-974-1882

Health Science Center

UT Health Science Center
910 Madison Avenue, Suite 827
Memphis, TN 38163
Phone: 901-448-7827


Copyright © 2025


University of Tennessee Campuses & Institutes

  • UT Knoxville
  • UT Knoxville
  • UT Chattanooga
  • UT Chattanooga
  • UT Southern
  • UT Southern
  • UT Martin
  • UT Martin
  • UT Health Science Center
  • UT Health Science Center
  • UT Institute of Agriculture
  • UT Institute of Agriculture
  • UT Institute for Public Service
  • UT Institute for Public Service
  • UT Alumni Association
  • UT Alumni Association
  • UT Foundation
  • UT Foundation
  • UT Research Park
  • UT Research Park
X